BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The results of these studies have shown that the used complexes allowed longer BCR-ABL kinase inactivation even at lower doses of IM compared with the previously formed microscale formulation polyelectrolyte microcapsules, giving hope that such complexes can be used with success to overcome drug resistance and prevent relapse in CML patients (55).